Can a JAK inhibitor halt rapid lung decline?
NCT ID NCT07737249
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the JAK inhibitor golidocitinib to standard high-dose steroids can improve lung function in people with rapidly progressive interstitial lung disease (RP-ILD). Participants receive either golidocitinib plus steroids or steroids plus other immunosuppressants for 12 weeks. The study measures changes in lung function, oxygen levels, chest CT scans, and safety outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- golidocitinib plus corticosteroid
- What this could lead to
- If successful, this could offer a new treatment option for people with rapidly worsening interstitial lung disease, potentially improving lung function and survival.
- What could go wrong
- This is an early phase 2 trial with only 60 participants, so results may not apply broadly. JAK inhibitors carry risks of infection and other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vibrating platform help people with stiff lungs breathe easier?
- Massive study tracks lung disease progression in 4,000 patients
- New pill aims to halt lung scarring in thousands
- Massive 10-Year study aims to unlock secrets of rare lung disease
- Could a cancer drug slow lung scarring? new trial tests anlotinib for IPF
- Lung cancer and scarred lungs: a dangerous duo under the microscope